Technology Partnership of Nagoya University, Inc.

One Copley Parkway, Suite 305, Morrisville, NC 27560

© Technology Partnership of Nagoya University, Inc.  All rights reserved.

Available Technologies

PHARMA & DRUGS

 

(for more information, click title to open PDF file)
 
A-59     Novel Biomarkers and Agents to Screen Molecular-Targeted Therapeutics for Peritoneal Metastasis from Gastric Cancer

NU Researchers identified Synaptotagmin VIII (SYT8) as a candidate biomarker specific to peritoneal metastasis.

A-60     Novel Biomarkers and Agents to Screen Molecular-Targeted Therapeutics for Hepatic Metastasis from Gastric Cancer

Nagoya University researchers conducted transcriptome analysis using a next-generation sequencing platform and identified major facilitator superfamily domain containing 4 (MFSD4) as a candidate biomarker for hepatic metastasis of GC.

A-61     Antibody that Inhibits Wnt Signal Activation Pathway

Although it is known that ADAM family proteases cause the severe bleeding from haemorrhagic snake venom, the detailed mechanism of the haemorrhage is unclear. Researchers at Nagoya University have found that the target of ADAM proteases is a Wnt/β-catenin signal receptor, LRP5/6 which controls cell differentiation and proliferation.

 

A-65     Method for Preparing Genetically-Modified T Cells Which Express Chimeric Antigen Receptor

The research team at Nagoya University has improved the large-scale T cell culture method and achieved the highest introduction efficiency in a non-viral system; over 50%, by mixing and co-culturing Genetically-modified T Cells with activated T Cells that were separately prepared.

A-66     Novel Artificial T cell Activating Adapter Molecules to Improve TCR-T Therapy

To improve the effect of TCR-T without modifying TCR affinity, researchers at Nagoya University have developed two artificial T cell activating adapter molecules (ATAMs), CD3ζ/CD28 and CD3ζ/4-1BB, for cancer immunotherapy.

A-67     A new animal model and therapeutic agent for synaptic dysfunction, FTLD and ALS

Researchers at Nagoya University have identified a potential therapeutic agent by developing a novel knockout mouse that presents the symptoms mimicking FTLD patients.

A-68     Novel Drug for the Treatment of Juvenile Myelomonocytic Leukemia

Nagoya University researchers have successfully identified a drug for the treatment of JMML using integrated molecular profiling.

A-69     Noble therapeutics targeting a neuromuscular disease, Spinal and bulbar muscular atrophy

Researchers in Nagoya University have successfully identified the therapeutics of SBMA targeting the spatiotemporal dysregulation of signaling pathways in SBMA. 

A-70     Novel biomarker to predict immunotherapy effect on cancer patients

Nagoya University researchers have successfully elucidated functional molecular mechanism of the ISLR, immunoglobulin superfamily containing leucin e-rich repeat, to develop highly sensitive biomarker as a checkpoint protein for Immunotherapies.